BjöndHealth (Columbus, OH)  is cloud-based, care management software as a service (SaaS) that identifies ready-to-change patients who will drive most medical costs, creates hyper-personalized, evidence-based care plans/workflows for identified patients, automates the collaborative execution of such workflows via mobile devices across the healthcare supply chain, and employs behavioral economics to induce and sustain healthy change.

Cirius Therapeutics

Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.


ConcertoHealth Inc. (Irvine, CA) has more than a decade of experience caring for the Medicare, Medicaid, frail and complex medical needs patient populations. The company addresses critical vulnerabilities for patients and health plans alike: expanded access to personalized primary care, chronic condition management and coordination of transitions between care settings. Through its ConcertoHealth Care Centers, the company provides healthcare services where and when they’re needed, delivering primary care and care coordination regardless the location – be it clinic, home, hospital or post-acute settings.

Delphinus Medical Technologies

Delphinus Medical Technologies, Inc (Plymouth, MI) is an innovation leader in automated whole breast ultrasound technology.  The company is developing its SoftView system to serve women with a transformational approach to breast imaging, particularly those with challenging dense breast tissue.

Intervention Insights

Intervention Insights (Cambridge, MA) is a health information services company helping community oncologists incorporate molecular oncology into their practice. The Company’s information services enable the oncology care team to more efficiently access and consider relevant, up-to-date medical evidence to support the appropriate utilization of molecular diagnostics and targeted therapeutics. The Insights services are designed to support each of the key stakeholders within the local community setting including community oncology practices, local pathologists, and third party payers.

Metabolic Solutions Development Company

Metabolic Solutions Development Company (Kalamazoo, MI) is a drug discovery and development company investigating new molecular targets and developing novel therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes.

NeoChord, Inc.

NeoChord, Inc. (Eden Prairie, MN) is developing technology invented by cardiac surgeons at the Mayo Clinic who were looking for less invasive ways to repair the mitral valve for the treatment of degenerative mitral regurgitation. The NeoChord DS 1000 device allows sternal sparing, beating heart, apical access to the mitral valve and functions as a delivery system for the placement of artificial chordae tendineae (chords). Ruptured or elongated chords are the primary reason for surgery on the mitral valve today.


Nymirum (Ann Arbor, MI) is the RNA Structure Company; providing RNA Structure Core solutions for basic, translational, and drug discovery research. Just as Protein Structure Core facilities emerged over a decade ago due to genome sequencing projects, RNA Structure Core capabilities are now needed in response to the explosion of newly identified RNAs from functional genomics projects.

Nymirum’s solutions portfolio includes software, support and services, and traditional pharmaceutical development partnerships.

PrevaCept Infection Control

PrevaCept (Broomfield, CO) is developing PrevaCept Lock Solution, an anti-microbial catheter lock solution, to prevent bacterial and fungal central line associated bloodstream infections (CLABSI).


Sierra Oncology

Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. We are an ambitious oncology-focused company, oriented towards achieving the successful registration and commercialization of our product candidates. We have a world-class management team with a proven track record of success in oncology drug development and we are advancing an emerging pipeline of next generation therapies that target the DNA Damage Response (DDR) network.